Anti-IL-17RA monoclonal antibody
Brodalumab
Brand names: Kyntheum
Adult dose
Dose: 210mg SC weeks 0, 1, 2 then q2w
Route: Subcutaneous
Frequency: q2w (after loading)
Clinical pearls
- NICE TA511: severe plaque psoriasis when other systemic therapies inadequate
- BAD psoriasis biologic guidance — TB/HBV/HCV screen pre-treatment
- MHRA monitoring of suicidal behaviour signal (assess mood)
Contraindications
- Active Crohn's disease
- Active serious infection / TB
- Pregnancy
- Hypersensitivity
Side effects
- URTI
- Candidiasis
- Neutropenia
- Suicidal ideation (boxed warning — historical)
- Inflammatory bowel disease exacerbation
- Injection-site reactions
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- TB / HBV / HCV at baseline
- Mood
- Infections
- FBC
Reference: BNF; NICE TA511; BAD biologics guideline; MHRA; SmPC; https://bnf.nice.org.uk/drugs/brodalumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD